1174122-54-3

Basic information

• Product Name: Retagliptin
• Synonyms: Retagliptin
• CAS NO: 1174122-54-3
• Molecular Formula: C₁₉H₁₈F₆N₄O₃
• Molecular Weight: 464.3616392
• Mol File: 1174122-54-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Retagliptin(CAS DataBase Reference)
• NIST Chemistry Reference: Retagliptin(1174122-54-3)
• EPA Substance Registry System: Retagliptin(1174122-54-3)

Safety Data

• Hazardous Substances Data: 1174122-54-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Retagliptin is used as an antidiabetic agent for improving glycemic control in patients with type 2 diabetes. It achieves this by blocking the DPP-4 enzyme, which increases the levels of incretin hormones, thus helping to manage blood sugar levels effectively.

Upstream product

• 1358715-37-3 methyl 3-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine-1-carboxylate 
• 1174039-18-9 (R)-7-[3-tertbutoxycarbonylamino-4-(2,4,5-tri-fluorophenyl)butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester 

Downstream Products

• 1256756-92-9 (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester sulfate 

Relevant articles and documents

Intermediate of DPP-IV inhibitor, preparation method thereof and method of preparing DPP-IV inhibitor through intermediate

The invention relates to an intermediate of a DPP-IV inhibitor (as shown in a formula I), a preparation method thereof and a method of preparing the DPP-IV inhibitor through the intermediate. The method of preparing the DPP-IV inhibitor specifically comprises the following steps of: performing a reaction on a cyclic chiral beta-amino aryl butyric acid derivative (as shown in a structural formula I) and a compound III; and then removing an amido protecting group to prepare the needed DPP-IV inhibitor. The method provided by the invention is simple and convenient to operate, low in cost and suitable for large-scale production. The formula is as shown in the description.

Preparation method of 3R-amino substituted butyrylamide derivative

The invention relates to a preparation method of a 3R-amino substituted butyrylamide derivative. The preparation method of the 3R-amino substituted butyrylamide derivative comprises the following steps: carrying out hydrogenation reduction on enamine II for preparing 3R,3S-amino substituted butyrylamide racemate III; carrying out resolution, and filtering, so as to obtain 3R-amino substituted butyrylamide R(-) mandelate with high ee% value, alkalifying to obtain the 3R-amino substituted butyrylamide derivative; and oxidizing the obtained mother liquor, so as to obtain enamine II in a recycling manner, and repeating oxidation-reduction cycle for multiple times until products at specified yield are obtained. The preparation method of the 3R-amino substituted butyrylamide derivative has the advantages that a cyclic method is utilized for converting 3S-amino substituted butyrylamide racemate or 3R,3S-amino substituted butyrylamide mixture in any ratio into the 3R-amino substituted butyrylamide derivative with high ee% value, so that the mother liquor is effectively utilized; meanwhile, an expensive catalyst or asymmetric reductive amination with high demand condition does not need to be adopted, thereby being beneficial to reduction of cost and clean production.

Salts of Methyl (R)-7-[3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyryl]-3-Trifluoromethyl-5,6,7,8-Tetrahydro-Imidazo[1,5-A]Pyrazine-1-Carboxylate

The pharmaceutically acceptable salts of methyl (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylate, their preparation methods and their use for preparing anti-diabetic medicaments a